MALVERN, Pa., Nov. 13, 2018 /PRNewswire/ -- NeuroStar® Advanced Therapy, the established leader in transcranial
magnetic stimulation (TMS), announced an expanded partnership with GRW Health, the parent company of Harmony and Transformations TMS. Transformations TMS will offer NeuroStar
Advanced Therapy at six new locations across Pennsylvania and West
Virginia. Harmony, a clinic dedicated to the treatment of mental illness and restoration of mental well-being, has offered
NeuroStar at three of its locations since December 2017. With this most recent expansion, GRW
Health will now have 11 NeuroStar TMS systems installed across their nine locations.
NeuroStar Advanced Therapy uses magnetic pulses to awaken areas of the brain that are underactive in depression. With its
advanced technology, NeuroStar Advanced Therapy offers doctors real-time feedback and delivers enhanced care with its precise and
accurate targeting, providing reliable and consistent treatment. In an open-label clinical trial, 58% of patients significantly
responded to treatment, and 37% achieved complete remission of their depression symptoms with NeuroStar Advanced Therapy
TMS.1
"I am thrilled to be expanding our relationship with GRW Health to increase patient access to this transformative treatment
and help more people find relief from their depression," said Chris Thatcher, President and CEO of
Neuronetics, Inc. "GRW Health's increased investment in NeuroStar TMS demonstrates their commitment to the proven efficacy of
this non-drug treatment option and its ability to transform lives."
In 2018, Transformations TMS has already treated more than 75 patients and expects to see more than 100 patients across the
Transformations TMS locations by the end of the year.
"We strive for the highest quality of psychiatric care and we're excited to offer NeuroStar Advanced Therapy at more of our
locations across Pennsylvania and West Virginia," said Dr.
Ryan Wakim, founder and president of GRW Health. "We have a committed team looking to help
alleviate our patients' depression symptoms as much as possible, and we know NeuroStar works and provides our patients with a
chance at long-term remission from depression. In fact, I've been so impressed by the results I've seen, I've even recommended
NeuroStar to my own family members struggling with depression."
Since receiving FDA clearance in 2008 as a safe and effective treatment for adult patients with MDD, NeuroStar Advanced
Therapy has become a game-changer in the treatment of depression and offers hope to the 5.5 million adults in the U.S. treated
for depression who do not achieve remission with antidepressant medication.234 With widespread insurance coverage by
most commercial and government health plans including Medicare and Tricare, the non-drug therapy is available by prescription and
typically administered daily in a doctor's office for four to six weeks, with treatment sessions performed in as little ~19
minutes.* Unlike electroconvulsive therapy (ECT), NeuroStar Advanced Therapy is non-invasive and allows patients to resume daily
activities immediately following treatment sessions. It is also free from systemic side effects often associated with
antidepressant medications.5
Transformations TMS locations will now include Denver, CO; Fox
Chapel, PA; McMurray, PA; Monroeville, PA; Mt. Lebanon, PA; Robinson, PA; Wexford,
PA; Weirton, WV and Wheeling, WV.
Visit www.NeuroStar.com for more information about
NeuroStar Advanced Therapy.
About NeuroStar® Advanced Therapy
NeuroStar® Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form
of neuromodulation. NeuroStar Advanced Therapy is the #1 TMS choice of doctors for patients with MDD, and is widely available
across the United States.
NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition,
there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and
reimbursement for NeuroStar Advanced Therapy.
NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from
prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients
treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission
compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05).6 The most common side effect is
pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with
non-removable conductive metal in or near the head.
NeuroStar® is a registered trademark of Neuronetics, Inc. (NASDAQ: STIM). For more information and full safety and prescribing
information, visit www.neurostar.com.
1 Carpenter LL, et al. Depress Anxiety, (2012)
* Treatment time may vary depending on doctor's recommendation.
2 Kessler RC, et al. JAMA, (2003)
3 https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed 1/16/2018
4 Gaynes BN et al., Cleveland Clinic Journal of Medicine 2008;75(1):57-66
5 Janicak PG, et al. J Clin Psychiatry, (2008)
6 George MS, et al. Arch Gen Psychiatry, (2010)
View original content:http://www.prnewswire.com/news-releases/neurostar-advanced-therapy-and-transformations-tms-expanding-partnership-to-increase-patient-access-to-depression-treatment-300748911.html
SOURCE NeuroStar Advanced Therapy